u/hsa_math

Yes — four nations, four pathways, and threads that ignore that give people the wrong answer confidently.

and once you are paying, pre-tax dollars change the real cost by about a third. i nearly missed that for a year.

Push back: an open-label extension tells you about the people who stayed. That is a different question.

STEP is semaglutide obesity, SURMOUNT is tirzepatide obesity, they are not interchangeable

Correction: that threshold is your ICB’s, not a national one. They differ and they change by year.

Read both programme names carefully after mixing them up in a comment and being politely corrected.

Yes. The appendix tables are where the subgroup and the adverse event detail actually live.

Yes — four nations, four pathways, and threads that ignore that give people the wrong answer confidently.

Phase 2 or phase 3?

private and NHS pathways are not a ladder, they are separate routes

a plateau is not a failure and it is not a personality

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

Discharge from a specialist service at goal is a normal end point of that pathway. Whether prescribing continues in primary care afterwards is a local decision and is worth asking about at the start rather than at the end.

Open-label extensions lose their randomisation. Anybody still enrolled at week 104 is a selected group and the numbers describe that group.

What did the confidence interval look like?

Agreed. The ICB variation is the thing that makes national advice useless here.

a plateau is not a failure and it is not a personality

waist is the measurement that keeps moving during a scale stall

Which pharmacy, and what did they quote for the month rather than the first month?

Agreed — and keeping the letters with dates is what makes any later challenge possible.

Scotland, Wales and Northern Ireland have their own arrangements. An answer that begins with "in England" should say so, and most of the confusion here comes from answers that do not.

Yes. The middle is where everybody actually lives and almost nobody posts from it.

Not convinced. Oral semaglutide is a peptide formulated with an absorption enhancer; the comparison you are making does not hold.

Text-only posting removes the comparison mechanism that makes image boards difficult, which is why this community adopted the rule and has kept it.

Stalled for 21 weeks and measured my waist out of stubbornness. It had moved. The scale had not.

A private prescription is an independent route: it does not affect NHS list position, and it is not a step in the same pathway.

Disagree — that figure is from the diabetes programme and you are quoting it as an obesity endpoint.

How long was the randomised phase before any extension?

The scheme cap in Ireland was the single most useful thing I learned in a year of reading this board.

Concentrations can differ between products and between pharmacies. Switching mid-titration means redoing the arithmetic rather than carrying the old unit count across.

phase 3 is where the comparison becomes fair

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

The analytical point, which this board keeps getting wrong by importing habits from the peptide side.

For a peptide, purity is typically reported as area percent by HPLC with identity by mass spectrometry, and the impurity classes are things like deletion and oxidation products. For a small molecule the relevant impurities are synthetic intermediates, degradants and residual solvents, and identity is established differently.

So the certificate you would want looks different, the questions to ask are different, and a "purity" figure quoted here is not comparable to one quoted on the peptide boards. Anybody posting a result should say what method produced it, which is good practice everywhere and essential here.

a plateau is not a failure and it is not a personality

Absolute or relative risk reduction?

oral semaglutide is a peptide with an absorption enhancer, this is not that

BMI thresholds vary by ICB and by year

Intention-to-treat analyses everybody randomised regardless of what they did afterwards. Completer analyses only those who finished. The second is systematically more flattering and both are legitimate if labelled.

Scotland, Wales and Northern Ireland have their own arrangements. An answer that begins with "in England" should say so, and most of the confusion here comes from answers that do not.

How to read one of these papers in fifteen minutes, in the order that actually helps.

Start with the registered protocol and check the primary endpoint against what is reported. Then the methods: who was included, what the comparator was, how long the randomised phase ran. Then the discontinuation numbers, which are a tolerability result and are usually in a supplementary table.

Only then the efficacy figure, and read the interval rather than the point estimate. Finish with the limitations section, which is where the authors say what they actually think.

Fifteen minutes, and you will know more than any thread summarising it.

Milligram comparisons across molecule classes are meaningless. Potency is a property of the molecule at its receptor, not of the number on the label.